Abstract: A viral vector comprises a transgene construct. In some embodiments, the transgene construct is a DNA sequence comprising a promoter element, a retinal gene's open reading frame being longer than 10 kb, and a terminator sequence. In other embodiments, the transgene construct is a DNA segment of retinal genes longer than 10 kb.

Abstract: The present disclosure provides a universal influenza virus vaccine. A composition for a universal influenza virus vaccine comprises at least two, preferably more than two, different influenza hemagglutinin (HA) derived antigens. The HA proteins from which the antigens are derived have a hypervariable region located between conserved cysteines at positions 52 and 277, and the hypervariable region is deleted in the antigens. The at least two antigens each have a similarity with HA molecules of more than one influenza serotype in excess of 60, or 70, or 80, as calculated by the emboss explorer cons program.

Abstract: The present disclosure provides a hybrid ligand molecule. The hybrid ligand molecule has two antibody combining sites. The first antibody combining site binds to an effector cell receptor complex structure of an effector cell. The second antibody combining site is a target cell-specific antibody combining site. The first and second antibody combining sites are linked.

Abstract: A multivalent vaccine for preventing CoV infection includes more than one protein antigen derived from antigens encoded within a CoV genome. At least one of the more than one protein antigen derived from antigens encoded within a CoV genome is a protein antigen, RNA-encoded genetic information, DNA-encoded genetic information, or genetic information within a genetic vector.

Abstract: In one aspect, the embodiments disclosed herein relate to the production of fully-deleted adenovirus-based gen delivery vectors packaged without the use of an adenoviral helper virus, and more particularly in their use in the transfer of genes and the expression of proteins, vaccine development, and cell engineering. In another aspect, the production of adenoviral vectors deleted of all adenoviral genes is described that carry genes of interest with detrimental or toxic activities to eukaryotic cells.

Abstract: A vaccine for preventing CoV infection includes at least one DNA, RNA or protein sequence for S protein with at least one modification which is a full deletion or partial deletion of the SI region or a partial or full replacement of the SI region. A method of vaccinating a mammal subject against infection from at least one group of CoV includes separating a broad group of CoV into homology groups, creating a modified S protein containing at least one modification at its S1 region, and identifying at least one consensus sequence for each homology group which has a sequence identity of greater than 60% to all other members of the homology group. The consensus sequence is a protein sequence for the modified S protein, a DNA sequence encoding the modified S protein, and an RNA sequence encoding the modified S protein.

Abstract: A vaccine for preventing ?-CoV infection includes at least one viral vector containing a ?-CoV DNA sequence which codes the S protein for the ?-CoV. The ?-CoV RNA sequence can be a SARS-2 ?-CoV DNA sequence. The vaccine may further includes a packaging plasmid based on an adenovirus. The viral vector and packaging plasmid can be contained in a packaging cell and encapsidated in a capsid. A method of vaccinating a mammal subject against infection from at least one group of ?-CoV includes separating a broad group of ?-CoV into homology groups based on similarities in the ?-CoV RNA sequences which code for their S proteins, identifying at least one consensus sequence for each homology group which has a sequence identity of greater than 60% to all other members of the homology group, and preparing a viral vector including at least a portion of the consensus sequence from at least one homology group.

Abstract: Introduction of DNA fragments into eukaryotic cells exposes them to cellular enzymes, such DNases that have the ability to destroy these DNA fragments and thus reduce the function. The invention provides means and methods reducing the enzymatic destruction of linear DNA fragments transfected into cells. To this purpose, expression constructs are designed that carry genes for proteins that bind to DNA fragments and prevent the enzymatic destruction of the linear DNA fragments. The use of these genes and expression vectors in modifying packaging cells for the enhanced production of viral gene therapy vectors and methods of making these packaging cells are provided.

Abstract: The embodiments disclosed herein relate to the design, engineering and production of replication-deficient gene delivery vectors that are based on aviadenoviruses. More particularly their use is described in the transfer of genes, genetic engineering of cells and animals, the expression of proteins the development of vaccines. In some embodiment, the designs and packaging of partially deleted aviadenovirus vectors are disclosed. In other embodiments, the designs and packaging of fully deleted aviadenovirus vectors, the propagation of replication-deficient aviadenovirus vectors, and the characteristic and engineering of host cells are disclosed. In other embodiments, the use of such vectors in veterinary medicine is described.

Abstract: The production of gene transfer vectors that have been designed as replication deficient constructs can be inefficient, thus limiting their broad use in medicine. The present invention provides a solution to this problem. It describes how the production efficiencies can be enhanced for gene transfer vectors that are produced by the transfer of DNA and RNA into production cells. The present invention lies m the use of cell cycle control in optimizing the production of gene transfer vectors. The subject of this patent is the modification of cell growth and physiology to enhance the efficiency of vector production. An example is given for the effect of certain media components on the cell cycle and production rate of a fully deleted helper virus independent adenoviral vector. Other applications of this technology are listed.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

Abstract: The present invention provides compositions and methods for specifically inhibiting host immune responses against autoantigens. In particular, compositions and methods combining CD8 polypeptide expression with autoantigen expression or presentation are described for specifically inhibiting the humoral and cellular components of the host immune response to autoantigens.

Abstract: The present invention relates to a product and process for suppressing an immune response using a T lymphocyte veto molecule capable of blocking cell surface molecules responsible for T cell activation. Disclosed is a CD4 or CD2 molecule, associated with an immunoglobulin molecule capable of binding to a major histocompatibility antigen. Also disclosed is a method to produce a T lymphocyte veto molecule, a therapeutic composition comprising a T lymphocyte veto molecule and methods to use T lymphocyte veto molecules in therapeutic processes requiring suppression of an immune response.

Abstract: The present invention relates to a product and process for suppressing an immune response using a T lymphocyte immunosuppression molecule capable of blocking cell surface molecules responsible for T cell activation. Disclosed is a CD4 or CD2 molecule, associated with an immunoglobulin molecule capable of binding to a major histocompatibility antigen. Also disclosed is a method to produce a T lymphocyte molecule, a therapeutic composition comprising a T lymphocyte immunosuppression molecule and methods to use T lymphocyte immunosuppression molecules in therapeutic processes requiring suppression of an immune response.

Abstract: A hybrid ligand molecular composed of an antibody combining site that binds to a T cell receptor complex structure and is capable of activating cytotoxic T lymphocytes linked to a target cell-specific antibody is disclosed. This ligand molecule can bind to an antigen on the surface of a target cell and to cytotoxic effector T lymphocyte cell receptor complex structures. A composition and a method for killing tumor cells with the hybrid ligand molecule of this invention are provided.